Nu-Med Plus annual total liabilities
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nu-Med Plus Total Liabilities Growth & History (NUMD)
Nu-Med Plus's total liabilities was $279,189 for fiscal 2025.
View full Nu-Med Plus company overviewNu-Med Plus annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $279,189 | $54,720 | +24.38% |
| 2024 | 2024-12-31 | $224,469 | $64,262 | +40.11% |
| 2023 | 2023-12-31 | $160,207 | $17,637 | +12.37% |
| 2022 | 2022-12-31 | $142,570 | −$11,951 | −7.73% |
| 2021 | 2021-12-31 | $154,521 | $65,089 | +72.78% |
| 2020 | 2020-12-31 | $89,432 | −$326,779 | −78.51% |
| 2019 | 2019-12-31 | $416,211 | $41,722 | +11.14% |
| 2018 | 2018-12-31 | $374,489 | $36,012 | +10.64% |
| 2017 | 2017-12-31 | $338,477 | −$4.1M | −92.44% |
| 2016 | 2016-12-31 | $4.5M | −$10.8M | −70.75% |
| 2015 | 2015-12-31 | $15.3M | $15.0M | +5633.81% |
| 2014 | 2014-12-31 | $266,828 | — | — |
| 2012 | 2012-12-31 | $156,487 | — | — |
Nu-Med Plus quarterly total liabilities
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $280,395 | $25,538 | +10.02% |
| Q1 2026 | 2026-03-31 | $294,340 | $54,138 | +22.54% |
| Q4 2025 | 2025-12-31 | $279,189 | $54,720 | +24.38% |
| Q3 2025 | 2025-09-30 | $263,708 | $52,326 | +24.75% |
| Q2 2025 | 2025-06-30 | $254,857 | — | — |
| Q1 2025 | 2025-03-31 | $240,202 | $62,609 | +35.25% |
| Q4 2024 | 2024-12-31 | $224,469 | $64,262 | +40.11% |
| Q3 2024 | 2024-09-30 | $211,382 | $65,679 | +45.08% |
| Q1 2024 | 2024-03-31 | $177,593 | $27,295 | +18.16% |
| Q4 2023 | 2023-12-31 | $160,207 | $17,637 | +12.37% |
| Q3 2023 | 2023-09-30 | $145,703 | — | — |
| Q2 2023 | 2023-06-30 | $152,096 | — | — |
| Q1 2023 | 2023-03-31 | $150,298 | −$46,639 | −23.68% |
| Q4 2022 | 2022-12-31 | $142,570 | −$11,951 | −7.73% |
| Q1 2022 | 2022-03-31 | $196,937 | $102,879 | +109.38% |
| Q4 2021 | 2021-12-31 | $154,521 | $65,089 | +72.78% |
| Q3 2021 | 2021-09-30 | $121,253 | −$306,633 | −71.66% |
| Q2 2021 | 2021-06-30 | $90,781 | −$349,870 | −79.40% |
| Q1 2021 | 2021-03-31 | $94,058 | −$320,488 | −77.31% |
| Q4 2020 | 2020-12-31 | $89,432 | −$326,779 | −78.51% |
| Q3 2020 | 2020-09-30 | $427,886 | $40,807 | +10.54% |
| Q2 2020 | 2020-06-30 | $440,651 | $80,612 | +22.39% |
| Q1 2020 | 2020-03-31 | $414,546 | $35,377 | +9.33% |
| Q4 2019 | 2019-12-31 | $416,211 | $41,722 | +11.14% |
| Q3 2019 | 2019-09-30 | $387,079 | $29,112 | +8.13% |
| Q2 2019 | 2019-06-30 | $360,039 | −$1,502 | −0.42% |
| Q1 2019 | 2019-03-31 | $379,169 | $33,134 | +9.58% |
| Q4 2018 | 2018-12-31 | $374,489 | $36,012 | +10.64% |
| Q3 2018 | 2018-09-30 | $357,967 | −$56,466 | −13.62% |
| Q2 2018 | 2018-06-30 | $361,541 | −$52,675 | −12.72% |
| Q1 2018 | 2018-03-31 | $346,035 | −$40,363 | −10.45% |
| Q4 2017 | 2017-12-31 | $338,477 | −$4.1M | −92.44% |
| Q3 2017 | 2017-09-30 | $414,433 | $24,943 | +6.40% |
| Q2 2017 | 2017-06-30 | $414,216 | $46,753 | +12.72% |
| Q1 2017 | 2017-03-31 | $386,398 | $5,433 | +1.43% |
| Q4 2016 | 2016-12-31 | $4.5M | −$10.8M | −70.75% |
| Q3 2016 | 2016-09-30 | $389,490 | $110,764 | +39.74% |
| Q2 2016 | 2016-06-30 | $367,463 | $91,714 | +33.26% |
| Q1 2016 | 2016-03-31 | $380,965 | $104,385 | +37.74% |
| Q4 2015 | 2015-12-31 | $15.3M | $15.0M | +5633.81% |
| Q3 2015 | 2015-09-30 | $278,726 | $11,898 | +4.46% |
| Q2 2015 | 2015-06-30 | $275,749 | $16,647 | +6.42% |
| Q1 2015 | 2015-03-31 | $276,580 | $19,122 | +7.43% |
| Q4 2014 | 2014-12-31 | $266,828 | $46,466 | +21.09% |
| Q3 2014 | 2014-09-30 | $266,828 | $54,502 | +25.67% |
| Q2 2014 | 2014-06-30 | $259,102 | $24,410 | +10.40% |
| Q1 2014 | 2014-03-31 | $257,458 | $58,570 | +29.45% |
| Q4 2013 | 2013-12-31 | $220,362 | $63,875 | +40.82% |
| Q3 2013 | 2013-09-30 | $212,326 | — | — |
| Q2 2013 | 2013-06-30 | $234,692 | — | — |
| Q1 2013 | 2013-03-31 | $198,888 | — | — |
| Q4 2012 | 2012-12-31 | $156,487 | — | — |
Nu-Med Plus total liabilities trends
Over the last five fiscal years, Nu-Med Plus's total liabilities increased from $89,432 to $279,189, a change of $189,757. The latest reported quarter, Q2 2026, shows $280,395.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nu-Med Plus source filings ↗